DUGGAN ROBERT W 4

What Happened
Robert W. Duggan, CEO of Summit Therapeutics (SMMT), reported a purchase of 100,000 shares on June 4, 2026. The shares were acquired at $14.60 per share for a total reported value of $1,460,000. The transaction is reported under code “P” (purchase) and is listed as an open market or private purchase.

Key Details

• Transaction date: 2026-06-04; Price: $14.60 per share; Shares: 100,000; Total value: $1,460,000.
• Transaction type: Purchase (code P) — reported as open market/private purchase.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: The filing includes a disclaimer (F1) where the reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.
• Filing timeliness: The Form 4 was filed with the same date as the reported transaction (no late filing indicated in the provided data).

Context
Purchases by a company insider are commonly viewed as a stronger disclosure signal than sales because they require personal cash outlay; this report documents a cash purchase rather than an option exercise or award. The footnote clarifies the reporting person’s limited claimed beneficial ownership; it does not by itself explain the ownership structure or motivation for the purchase.